Search | IOVS | ARVO Journals

View

Showing 1 – 16 of 16

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Faricimab in neovascular age-related macular degeneration: updated week 48 efficacy, safety, and durability in the phase 3 TENAYA and LUCERNE trials

Nikolas London; Robyn H Guymer; Anna-Maria Demetriades; Carlos Quezada Ruiz; David Silverman; Jane Ives; Karen Basu; Hugh Lin

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3120. doi:

ARVO Annual Meeting Abstract June 2022

Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration (nAMD) using machine learning

Yusuke Kikuchi; Ales Neubert; Jian Dai; Carlos Quezada Ruiz

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2986 – F0256. doi:

ARVO Annual Meeting Abstract June 2021

A pilot study using machine learning (ML) to predict treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) using phase 2 trial data

Yusuke Kikuchi; Michael Kawczynski; Neha Anegondi; Jian Dai; Carlos Quezada Ruiz

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):82. doi:

ARVO Annual Meeting Abstract June 2021

Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design

Robyn H Guymer; Carlos Quezada Ruiz; Jeffrey R Willis; David Silverman; Jane Ives; Karen Basu; Balakumar Swaminathan; Aachal Kotecha; Heather Boston; Hugh Lin

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):429. doi:

ARVO Annual Meeting Abstract June 2021

Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani; Jeffrey Heier; Carlos Quezada Ruiz; Hugh Lin; David Silverman; Christopher Brittain; Jane Ives; Balakumar Swaminathan; Karen Basu; Tien Y Wong

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):428. doi:

ARVO Annual Meeting Abstract June 2021

Design and rationale of the YOSEMITE and RHINE trials: two phase 3 studies of faricimab in patients with diabetic macular edema

Nicole Eter; Jeffrey R Willis; Carlos Quezada Ruiz; Francis Abreu; Hugh Lin; David Silverman; Jane Ives; Karen Basu; Zdenka Haskova; Kemal Asik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1043. doi:

ARVO Annual Meeting Abstract June 2020

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial

Carl J Danzig; Hugh Lin; Pascal Guibord; David Silverman; Carlos Quezada Ruiz; Ivo Stoilov; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1160. doi:

ARVO Annual Meeting Abstract July 2018

Five-year progression of newly diagnosed untreated diabetic retinopathy in a real-world setting from a large US claims database

Andrew A Moshfeghi; Avanti Ghanekar; Ibrahim Abbass; Daniel Sheinson; Carlos Quezada-Ruiz; Vincent Garmo

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2599. doi:

ARVO Annual Meeting Abstract June 2017

Assessing the usability of the ranibizumab 0.5 mg prefilled syringe (PFS) by healthcare professionals in the US

Andrew N Antoszyk; Carl W Baker; Howard Cummings; Jorge Calzada; Joanna So; Carlos Quezada-Ruiz; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1953. doi:

ARVO Annual Meeting Abstract June 2017

Branch and central retinal vein occlusion: clinical pearls from trials of ranibizumab

Mimi Liu; David Eichenbaum; Sarah Taylor; Pin-wen Wang; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4624. doi:

ARVO Annual Meeting Abstract June 2017

Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO

Peter A Campochiaro; Raafay Sophie; Ann Clark; Na Lu; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4626. doi:

ARVO Annual Meeting Abstract June 2017

Ranibizumab versus verteporfin photodynamic therapy for myopic choroidal neovascularization: Results from RADIANCE

Nathan Steinle; Avanti Ghanekar; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5920. doi:

ARVO Annual Meeting Abstract September 2016

Differences in anti-vascular endothelial growth factor (anti-VEGF) injection frequency and costs for ranibizumab versus aflibercept in patients with diabetic macular edema (DME)

Carlos Quezada Ruiz; Yamina Rajput; Kathleen Wilson; Alice Huang; David M Smith; Helen Varker; Stephen S Johnston

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2101. doi:

ARVO Annual Meeting Abstract September 2016

Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year US claims analysis

Szilard Kiss; Yamina Rajput; Carlos Quezada Ruiz; Kathleen Wilson; Alice Huang; David M Smith; Helen Varker; Stephen S Johnston

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3335. doi:

ARVO Annual Meeting Abstract September 2016

Prevalence of drusen and conversion to neovascular age-related macular degeneration in the HARBOR study fellow eyes

Caroline R Baumal; Carlos Quezada Ruiz; Shamika Gune; Pin-wen Wang; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4967. doi:

ARVO Annual Meeting Abstract September 2016

Pan-retinal photocoagulation for diabetic retinopathy: is it one and done?

Victor H Gonzalez; Pin-wen Wang; Carlos Quezada Ruiz; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6355. doi:

Advertisement